Results 211 to 220 of about 10,879 (246)
Some of the next articles are maybe not open access.
Edaravone for acute ischaemic stroke
Cochrane Database of Systematic Reviews, 2011Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.To assess the efficacy and safety of edaravone for acute ischaemic stroke.We searched the ...
Feng, Shejun +7 more
openaire +4 more sources
Edaravone for acute intracerebral haemorrhage
Cochrane Database of Systematic Reviews, 2009Intracerebral haemorrhage (ICH) causes significant morbidity and mortality. Prognosis for ICH patients is poor. Edaravone may be safe and effective in reducing the risk of early death and improving long-term functional outcomes in survivors.To assess the safety and efficacy of edaravone for acute ICH.We searched the Cochrane Stroke Group Trials ...
Jie Yang +5 more
openaire +3 more sources
Experimental Neurology, 2009
0014-4886/$ – see front matter © 2009 Elsevier Inc. Al doi:10.1016/j.expneurol.2009.03.001 ⁎ Fax: +81 75 761 9780. E-mail address: ryosuket@kuhp.kyoto-u.ac.jp. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive and relatively selective degeneration of upper and lower motor neurons.
openaire +2 more sources
0014-4886/$ – see front matter © 2009 Elsevier Inc. Al doi:10.1016/j.expneurol.2009.03.001 ⁎ Fax: +81 75 761 9780. E-mail address: ryosuket@kuhp.kyoto-u.ac.jp. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive and relatively selective degeneration of upper and lower motor neurons.
openaire +2 more sources
International Journal of Pharmaceutics, 2009
We examined the effects of metabolic inhibitors on skin permeation of edaravone. SKF-525A, diclofenac sodium (DIC) and indomethacin (IND) were added to supernatant fluid (SF) of hairless rat (HR) skin homogenate. L-Cysteine (L-Cys) and benzotriazole (BTA), as pharmaceutical additives, were added to HR skin homogenate SF, and incubated at 37 degrees C ...
Toshiaki Sato +2 more
openaire +3 more sources
We examined the effects of metabolic inhibitors on skin permeation of edaravone. SKF-525A, diclofenac sodium (DIC) and indomethacin (IND) were added to supernatant fluid (SF) of hairless rat (HR) skin homogenate. L-Cysteine (L-Cys) and benzotriazole (BTA), as pharmaceutical additives, were added to HR skin homogenate SF, and incubated at 37 degrees C ...
Toshiaki Sato +2 more
openaire +3 more sources
Edaravone inhibits the disease activity in rheumatoid arthritis
Journal of Clinical Pharmacy and Therapeutics, 2006A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone. Polyarthralgia improved with a reduction in serum C-reactive protein concentration soon after the start of edaravone administration. The disease activity score 28 (DAS28) also decreased.
Kozo Hashimoto +4 more
openaire +3 more sources
Effects of edaravone on human neutrophil function
Acta Anaesthesiologica Scandinavica, 2005Background: Neutrophils play a crucial role in the antibacterial host defence system. Edaravone is used in critically ill patients who are often immuno‐compromised secondary to concomitant disease or immunosuppressive therapy. The aim of the current study was to assess the effect of edaravone, a novel free‐radical scavenger, on several aspects of ...
Hidefumi Obara +4 more
openaire +3 more sources
Is edaravone harmful? (A placebo is not a control)
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018Edaravone is delivered by long-term daily intravenous infusions, yet the risk of infusion was not considered in the design or analysis of studies examining the efficacy of edaravone in ALS. A reappraisal of the pivotal edaravone study (Study 19) on which claims of efficacy are based suggests that this risk cannot be dismissed, that the efficacy of ...
openaire +2 more sources
Edaravone for the treatment of amyotrophic lateral sclerosis
Expert Review of Neurotherapeutics, 2019Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all skeletal muscles, leading to death, mostly within 2-4 years from onset. To date, the anti-glutamatergic drug riluzole is the only drug that has been approved for the treatment of this disease; however, its efficacy is modest.
openaire +2 more sources
Edaravone administration in pivotal clinical Study 19
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019Recently, ALSFTD published an editorial entitled “Is edaravone harmful? (A placebo is not a control)” (1).
Benjamin Rix Brooks, Angela Genge
openaire +3 more sources
New Hybrid Structures Based on Memanthine and Edaravone Molecules
Doklady Biochemistry and Biophysics, 2023New hybrid structures based on memantine and edaravone molecules, in which the pyrazolone ring and adamantane fragments are linked by an alkyl linker, have been synthesized. It was found that in addition to the ability to block the intrachanal site of NMDA receptors, new hybrid compounds exhibit the property of blockers of the allosteric site of NMDA ...
V V, Grigoriev +6 more
openaire +2 more sources